The Employees’ State Insurance Corporation (ESIC) has issued an official notification regarding the revocation of a “Not of Standard Quality” (NSQ) order for a drug previously declared substandard.
Details of the Order
According to ESIC Headquarters Order No. U-25/12/NSQ/2022-MedV (E-12328)/618 dated 23.10.2025, which was uploaded on the ESIC website under Console No. 23188/2025 dated 24.10.2025, the earlier NSQ declaration for the following drug has been revoked with immediate effect:
- Item No.: 1438
- Drug Name: Iron Injection (Iron Sucrose 20 mg/ml)
- Packing: 5 ml Ampoule
- DG ESIC RC Code: 146C
- Batch No.: 231S10
Reason for Revocation
The revocation follows the outcome of a re-testing by the Central Drugs Laboratory (CDL), Kolkata, as per Test Report No. KOL/LS/2024-25/575 dated 16.07.2024. The re-evaluation concluded that the drug sample now meets the prescribed standard quality parameters, as confirmed by the Appellant Laboratory.
Key Points
- Previous Status: Declared “Not of Standard Quality” (NSQ)
- Revised Status: Declared “Of Standard Quality” after CDL re-test
- Effective Date of Revocation: Immediate (as per ESIC notification dated 23.10.2025)
- Testing Authority: CDL, Kolkata
Significance
This revocation underscores ESIC’s commitment to maintaining transparency, regulatory compliance, and scientific validation in its medical procurement and quality assurance processes. It also highlights the importance of appellate laboratory verification in ensuring accurate and fair quality determinations for pharmaceutical products used in ESIC healthcare facilities.